Tuesday, April 24, 2018
 
 
Company News: Page (1) of 1 - 04/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Mallinckrodt plc Announces $300 Million Debt Repayment
-- Company repays debt maturing April 2018 with cash on hand --
(April 16, 2018)

STAINES-UPON-THAMES, United Kingdom, April 16, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the $300 million repayment of unsecured, fixed-rate notes maturing April 15, 2018 with cash on hand. The debt was issued by Mallinckrodt International Finance SA in 2013 in preparation for the company's spin-off from its former parent (CUSIP #561234AD7).

Mallinckrodt logo

"One of our key strategic imperatives for 2018, as noted in our February earnings release, is ensuring execution on a highly disciplined capital allocation strategy. We have a particular focus on reducing debt and deleveraging the balance sheet throughout 2018. With this payment today, our total debt stands at less than $6.6 billion," said Matt Harbaugh, Executive Vice President and Chief Financial Officer of Mallinckrodt. "We will continue to look for opportunities to reduce debt further in 2018 and will allocate capital toward pursuing business development opportunities and share repurchases where they make strategic sense."



Mallinckrodt will report first quarter 2018 earnings results on May 8, 2018.

ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements concerning potential capital allocation activities, including but not limited to debt repayment, business development opportunities and share repurchases. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continued strength in the company's financial position, including cash flows; alternative uses of funds and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

CONTACTS

Investor Relations      
Daniel J. Speciale, CPA
Investor Relations and Strategy Officer
314-654-3638
[email protected]

Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
[email protected] 

Meredith Fischer
Chief Public Affairs Officer
314-654-3318
[email protected] 

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-plc-announces-300-million-debt-repayment-300630553.html

SOURCE Mallinckrodt plc

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Pro AV,Presentors,Business,Law,Business Issues,Presentation,Channel/Distribution,Events,USA,Medicine,Pregnancy,Surgery,Medication,Pregnancy,Science,Medical,Business,Other,
Related Sites: Digital Producer ,   Presentation Master ,   Oceania ,   DMN Newswire ,   itbusinessnet.com ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: DMN Newsletter ,   CMN Newsletter ,   KNews Newsletter ,   Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • National Oral Health Report: A State Of Decay
  • Global Medical Device Market 2018 with Forecasts to 2023 - Driven by Healthcare Expenditure / Technological Development / Aging Population / Chronic Diseases
  • Orthodontic Supplies Market to Hit 8.9% CAGR to 2023, Led by Align Technology, Inc. (US), 3M Company (US), and Danaher Corporation (US)
  • New Orleans' GAINSWave Offers GAINSWave® in Louisiana
  • Hearing Aids Market Is Estimated To Generate Revenues Worth USD 4.5 Billion By 2024: Grand View Research, Inc.

    Cancer
  • MOLOGEN AG: Announcement of the new dates for the publication of the Annual Financial Statements 2017 and the 2018 Annual General Meeting
  • SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline - June 19, 2018
  • Generic Injectables Market to Generate a Revenue of US$ 150 Bn by 2025, Says TMR
  • Anpac Bio Wins 2018 International 'BIG Innovation Award'
  • Health Tourism Market 2018 Global Industry Size, Emerging Trends, Share, Growth Factors, with growing at a CAGR of 15.4% Forecast by 2025
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines